{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-308769","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.751748+00:00","generated_at":"2026-05-16T14:14:56.207227+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi Therapeutics appoints David Hastings as CFO effective January 6, 2026","bullets":["David Hastings previously served as CFO of Arbutus Biopharma (June 2018–March 2025).","Base salary set at $522,000; annual bonus target up to 40% of base salary.","Receives option to purchase 375,000 shares, vesting 25% on first anniversary and monthly thereafter.","Eligible for separation benefits under the Executive Separation Benefits and Retention Plan.","Standard indemnification agreement to be entered with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-308769","json":"https://secwatch.observer/filing/0001193125-25-308769.json","markdown":"https://secwatch.observer/filing/0001193125-25-308769.md","text":"https://secwatch.observer/filing/0001193125-25-308769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000119312525308769/0001193125-25-308769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000119312525308769/trvi-20251201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:14:56.207227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}